IMPROVED OVERALL AND EVENT FREE SURVIVAL WITH ADAPTED BERLIN-FRANKFURT-MUNSTER (BFM)RISK STRATIFIED TREATMENT IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA-SINGLE CENTRE EXPERIENCE FROM SOUTH INDIA
Abstract
BACKGROUND: Paediatric acute lymphoblastic leukemia (ALL) has a reported five year overall survival reaching
over 90% in high income countries(HICs).Overall survival in India ranged from 45-81%(commonly > 60%) and Event
free survival ranged from 41-70%(commonly > 50%)
AIM: To analyse the outcome with a uniform protocol adapted from Berlin-Frankfurt-Münster (BFM) protocol used in all Pediatric ALL
patients.
METHOD: After institutional research board approval , records of consecutive children with newly diagnosed with B cell and T cell Acute
lymphoblastic leukemia/lymphoma (ALL) between 1 and 14 years of age at the time of diagnosis and underwent treatment in the institution from
1/1/10 to 31/12/18 were reviewed .Patient treatment was stratified according to BFM relapse risk criteria to standard risk(SR), Intermediate
risk(IR) and high Risk(HR).
RESULTS: One hundred and twenty eight children consecutively treated for acute lymphoblastic leukemia/ lymphoma with ages ranging
from 1-14 years were analysed. The estimated 5year overall survival and Event free survival by Kaplan meier method were 82.3+/- 3.4% and
79.8+/- 3.6%.
CONCLUSIONS: Adherence to globally accepted treatment regimens along with best supportive care can bring out results similar to HICs.
Keywords
Full Text:
PDFReferences
a. 1.Arora RS, Eden TO, Kapoor G. (2009)Epidemiology of childhood cancer in India. IndianJ Canc;46:264e73.
Smitha Asthana,Satyanarayana Labani,Swathi Mehrana, Sameer Bakshi. (2018)Incidence of childhood leukemia and lymphoma in India.Pediatric Hematology Oncology Journal,Volume 3, Issue 4, December, Pages 115-120.
. Farber S, Diamond LK, Mercer RD, et al. (1948)Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid 374. N Engl J Med.;238:787–93. [PubMed: 18860765]
4. Frei E, Freireich EJ, Gehan E, et al. (1961)Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate. Blood.; 18:431–54.
Pinkel D. (1971)Five-year follow-up of “total therapy” of childhood lymphocytic leukemia. JAMA.;
216:648–52. [PubMed: 5279904]
Freeman AI, Weinberg V, Brecher ML, et al. (1983)Comparison of intermediate-dose methotrexate with
a. cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N
Engl J Med.; 308:477–84. [PubMed: 6571946]
Richards S, Pui CH, Gaynon P. (2013)Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG). Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukaemia. Pediatr Blood Cancer.; 60:185–195. [PubMed: 22693038]
Pui CH, Mullighan CG, Evans WE, Relling MV. (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood.; 120:1165–174. [PubMed: 22730540]
Conter V, Bartram CR, Valsecchi MG, et al: (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214,
Schrappe M, Valsecchi MG, Bartram CR, et al: (2011) Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood 118:2077-2084,
Pui CH, Campana D, Pei D, et al. (2009)Treating childhood acute lymphoblastic leukemia without cranial
irradiation. N Engl J Med.; 360:2730–41. [PubMed: 19553647]
Möricke A, Zimmermann M, Reiter A, et al. (2010)Long-term results of five consecutive trials in
a. childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to
2000. Leukemia.; 24:265–284. [PubMed: 20010625]
.Hunger SP, Lu X, Devidas M, et al. (2012)Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J
Clin Oncol.; 30:1663–1669. [PubMed: 22412151]
.Veerman AJ, Kamps WA, van den Berg H, et al. (2009)Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group
(DCOG) protocol ALL-9 (1997–2004). Lancet Oncol.; 10:957–966. [PubMed: 19747876]
.Vrooman LM, Stevenson KE, Supko JG, et al. (2013)Postinduction dexamethasone and individualized
a. dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with
b. newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber
c. Cancer Institute ALL Consortium Protocol 00–01. J Clin Oncol.; 31:1202–1210. [PubMed:
23358966]
.Yamaji K, Okamoto T, Yokota S, Watanabe A, et al. (2010)Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer.; 55:1287–95. [PubMed: 20535816]
.Yeoh AE, Ariffin H, Chai EL, et al. (2012)Minimal residual disease-guided treatment deintensification
a. for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute
b. lymphoblastic leukemia 2003 study. J Clin Oncol.; 30:2384–2392. [PubMed: 22614971]
.Vora A, Goulden N, Wade R, et al. (2013)Treatment reduction for children and young adults with low risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a
a. randomised controlled trial. Lancet Oncol.; 14:199–209. [PubMed: 23395119]
.Schmiegelow K, Forestier E, Hellebostad M, et al. (2010)Long-term results of NOPHO ALL-92 and
a. ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia.; 24:345–354. [PubMed: 20010622]
Ramandeep S Arora, Brijesh Arora . (2016)Acute leukemia in children: A review of the current Indian data.South Asian J Cancer. Jul-Sep; 5(3): 155–160.PMCID: PMC4991139PMID: 27606304
Varghese B, Joobomary AA, Savida P. (2018)Five-Year survival rate and the factors for risk-directed therapy in acute lymphoblastic leukemia. Indian J Med Paediatr Oncol;39:301-6.
.Kulkarni KP, Marwaha RK, Trehan A, Bansal D. (2009)Survival outcome in childhood ALL: Experience from a tertiary care centre in North India. Pediatr Blood Cancer. ;53:168–73. [PubMed: 19405133]
Swaminathan R, Rama R, Shanta V. (2008)Childhood cancers in Chennai, India, 1990-2001: Incidence and survival. Int J Cancer. ;122:2607–11. [PubMed: 18324630]
.Bajel A, George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, et al. (2008)Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatr Blood Cancer. ;51:621–5. [PubMed: 18688848]
25 Varghese B,Joobomary AA,Savida P(2018).Five year survival rate and the factors for risk directed therapy in acute lymphoblastic leukemia. Indian JMed Paediatr Oncol,39:301-6
Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U et al. (2015)Acute lymphoid leukemia (version 2.2015). Natl Comprehens Cancer Netw; 13: 1240–1279.
A. G. Freifeld, E. J. Bow, K. A. Sepkowitz et al., (2011) “Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america,” Clinical Infectious Diseases, vol. 52, no. 4, pp. e56–e93,.
Riehm H, Reiter A, Schrappe M, et al: (1987)Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study
ALL-BFM 83) [in German]. Klin Pa¨diatr 199:151-160,
Kulkarni KP1, Arora RS, Marwaha RK. (2011)Survival outcome of childhood acute lymphoblastic leukemia in India: a resource-limited perspective of more than 40 years.J Pediatr Hematol Oncol. Aug;33(6):475-9. doi: 10.1097/MPH.0b013e31820e7361.
Advani S, Pai S, Venzon D, Adde M, Kurkure PK, Nair CN, et al. (1999)Acute lymphoblastic leukemia in India: An analysis of prognostic factors using a single treatment regimen. Ann Oncol;10:167-76
Kapoor A, Kalwar A, Kumar N, Singhal MK, Beniwal S, Kumar HS, et al. (2016)Analysis of outcomes and prognostic factors of acute lymphoblastic leukemia patients treated by MCP841 protocol: A regional cancer center experience. J Res Med Sci;21:15.
Menon J, Mathews L, Purushothaman KK. (2008)Treating leukemia in a resource poor setting. Indian Pediatr;45:410-2.
Rajeswari B, Sukumaran Nair RK, Guruprasad CS, Nair M, Thankamony P, Parukutty K. (2018)Infections during induction chemotherapy in children with acute lymphoblastic leukemia – Profile and outcomes: Experience from a cancer center in South India. Indian J Med Paediatr Oncol;39:188-92.
Frehling E, Ritchey AK, Tubergen DG, Bleyer A. (2015)Acute lymphoblastic leukaemia. In: Kliegman RM, Stanton B,Geme JS, Schor NF, editors. Nelson Textbook of Paediatrics. 1st ed., Vol. 495. South Asia: Elsevier Health Sciences;. p. 2437 42.
Gupta A, Kapoor G, Jain S, Bajpai R. (2015)Absolute lymphocyte count recovery independently predicts outcome in childhood acute lymphoblastic leukemia: Experience from a tertiary care cancer center of a developing country. J Pediatr Hematol Oncol;37:e143-9.
Jayabose S, Kumar V, Dhanabalan R, Rajan P, Rathnam K, Viswanathan TK. (2015)Low-dose rasburicase in hematologic malignancies. Indian J Pediatr;82:458-61
Orgel E, Sposto R, Malvar J, Seibel NL, Ladas E, Gaynon PS, et al. (2014)Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children’s Oncology Group. J Clin Oncol;32:1331-7
Jatia S, Arora B, Vora T, Banavali S, Rajadhyaksha S, Patil D, et al. (2015)Community platelet donor drives and establishment of a voluntary donor registry: A novel strategy to enhance treatment compliance & outcomes of childhood cancers in LMIC. Pediatr Blood Cancer;62:S203.
Refbacks
- There are currently no refbacks.